HC Wainwright reiterated their buy rating on shares of Vascular Biogenics (NASDAQ:VBLT) in a report released on Thursday morning, AnalystRatings.com reports. They currently have a $3.00 price objective on the biopharmaceutical company’s stock.
Several other research analysts have also recently commented on the company. Chardan Capital reissued a hold rating and set a $3.00 target price on shares of Vascular Biogenics in a research note on Thursday. ValuEngine cut Vascular Biogenics from a hold rating to a sell rating in a research note on Wednesday, May 1st. Finally, Zacks Investment Research raised Vascular Biogenics from a sell rating to a hold rating in a research note on Saturday, March 30th.
Shares of NASDAQ VBLT traded down $0.02 during trading on Thursday, reaching $1.28. The stock had a trading volume of 1,550 shares, compared to its average volume of 86,469. Vascular Biogenics has a fifty-two week low of $0.60 and a fifty-two week high of $3.10. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $46.29 million, a PE ratio of -2.06 and a beta of -0.25.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06). Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 30.67%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $2.30 million. On average, equities analysts predict that Vascular Biogenics will post -0.61 earnings per share for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RBF Capital LLC acquired a new position in Vascular Biogenics during the 4th quarter worth $353,000. Morgan Stanley grew its stake in Vascular Biogenics by 19.7% during the 1st quarter. Morgan Stanley now owns 277,112 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 45,552 shares in the last quarter. First Republic Investment Management Inc. grew its stake in Vascular Biogenics by 7.4% during the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 10,000 shares in the last quarter. Acadian Asset Management LLC grew its stake in Vascular Biogenics by 272.3% during the 1st quarter. Acadian Asset Management LLC now owns 59,427 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 43,466 shares in the last quarter. Finally, Menta Capital LLC acquired a new position in Vascular Biogenics during the 1st quarter worth $35,000. 14.06% of the stock is owned by hedge funds and other institutional investors.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Read More: What is the Stochastic Momentum Index (SMI)?
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.